ANALISIS EFEKTIVITAS BIAYA OBAT ANTIHIPERTENSI DOSIS TUNGGAL PADA PASIEN HIPERTENSI TANPA PENYAKIT PENYERTA: SYSTEMATIC LITERATURE REVIEW

Andriyani Rahmah Fahriati, Adam Rizki Fadilah, Adelia Rahmawati, Dila Denisa, Eneng Uswatun Chasanah, Khalipatun Sahara, Nurhakiki Nurhakiki, Rizki Zaidan Agustian, Shifa Fauziah

Abstract


Hypertension is a disease that occurs in various countries, especially Indonesia, where financing and health care are increasingly expensive. Based on data from the World Health Organization (WHO) in 2019, there were around 1,13 billionhypertension sufferers worldwide. Hypertension is a condition where a person experiences an increase in blood pressure above normal limits which can cause disease and even death. Pharmacoeconomic research is considered a suitable solution for policy makers in determining cost-effective clinical alternative treatments. The increasing costs of chronic diseases make access and quality of health services increasingly expensive, so solutions are needed to reduce health financing problems. The method used is cost effectiveness analysis (CEA). This systematic literature review aims to analyze single antihypertensive drugs in hypertensive patients without comorbidities using various related literature. Data were collected prospectively that met the inclusion and exclusion criteria. CEA analysis is calculated by looking at the ACER (Average Cost Effectiveness Ratio) value. From the overall results of the literature review, the most cost-effective antihypertensive drug is amlodipine, with the highest ACER range of 955.66 and the lowest 7,611. So it can be concluded that the most cost-effective antihypertensive therapy is amlodipine.

Keywords


Hypertension; Antihypertensive; Cost_Effectiveness_Analysis; Monotherapy

References


Almasdy, D. 2015. Evaluasi penggunaan obat antidiabetik pada pasien diabetes mellitus tipe 2 disuatu Rumah Sakit Pemerintah Kota Padang-Sumatera Barat. Prosiding seminar nasional &workshop “perkembangan terkini sains farmasi & klinik 5”

Ansar, J., Dwinata, I., & M, A. (2019). Determinan Kejadian Hipertensi Pada Pengunjung Posbindu DiWilayah Kerja Puskesmas Ballaparang Kota Makassar. Jurnal Nasional Ilmu Kesehatan, 1(3), 28–35.

Astuti, V. W., Tasman, T., & Amri, L. F. (2021). Prevalensi Dan Analisis Faktor Risiko Hipertensi Di Wilayah Kerja Puskesmas Nanggalo Padang. BIMIKI (Berkala Ilmiah Mahasiswa Ilmu Keperawatan Indonesia), 9(1), 1–9. https://doi.org/10.53345/bimiki.v9i1.185

Depy Oktapian Akbar, Aldi Apdillah Setiawan, Fairuz Yaumil Jurnal Insan Farmasi Indonesia, 9-17, 2023

Kamri, M, A., Kosman, R., & Rahayu, D. (2021). Analisis Efektivitas Biaya Penggunaan Amlodipine Dibandingkan Kaptopril Pada Pasien Hipertensi Di RSUD Majane. Jurnal Ilmiah Ibnu Sina, 6(2), 262-271. https://e-jurnal.stikes-isfi.ac.id/index.php/JIIS/article/view/718

Kemenkes, R. (2018). Hasil Utama Riskesdas. 57,58.

Laumba, F., Citraningtyas, G., & Yudistira, A. (2017). Analisis Efektivitas Biaya (Cost Eff Ectiveness Analysis) Pada Pasien Gastritis Kronik Rawat Inap Di Rsu Pancaran Kasih Gmim Manado. PHARMACON Jurnal Ilmiah Farmasi-UNSRAT, 6(3), 315–323.

Much Ilham Novalisa Aji Wibowo, Uji Pipit Lestari, Wahyu Utaminingrum KONGRES XX & PERTEMUAN ILMIAH TAHUNAN IKATAN APOTEKER INDONESIA 2018, 503-508, 2018

Nurhalizah, I. (2020). Profil penggunaan obat antihipertensi di puskesmas ungaran berdasarkan lama pengobatan. Universitas Ngudi Waluyo.

Perawati, S., Andriani, M., & Utaka, T. (2021). Analisis Efektifitas Biaya Penggunaan Obat Hipertensi Amlodipin Dan Candesartan Pada Pasien Bpjs Rawat Inap Di Rumah Sakit Dr. Bratanata Jambi Tahun 2019. Pharma Xplore Jurnal Ilmiah Farmasi, 6(2), 47–54. https://doi.org/10.36805/farmasi.v6i2.1941

Perhi. (2019). Konsensus Penatalaksanaan Hipertensi 2019. Indonesian Society Hipertensi Indonesia, 1–90.

Safitri, W. W., Dewi, R., & Sutrisno, D. (2021). Analisis Efektivitas Biaya Penggunaan Metildopa Dibandingkan Dengan Nifedipine Pada Pasien Preeklampsia Rawat Inap Di RSUD H. Abdul Manap Kota Jambi. Jurnal Farmasi Udayana, 10(2), 126. https://doi.org/10.24843/jfu.2021.v10.i02.p03

Wardani, A., & Yuswantina, R. (2023). Analisis Efektivitas Biaya Penggunaan Obat Hipertensi Amlodipin dan Candesartan pada Pasien Hipertensi di Klinik Merah Putih Ungaran. Journal of Holistics and Health Sciences Vol. 5, No. 2. https://eabdimas.unw.ac.id/index.php/jhhs/article/view/352

Wicaksono, B. D., Wibowo, Sugiyanto, & Hasana, A. R. (2023). Cost Effectiveness Analysis Amlodipin dan Nifedipin pada Pasien Hipertensi Rawat Inap di Rumah Sakit Panti Waluya. FARMASIS: Jurnal Sains Farmasi, 4(2), 85–92. https://doi.org/10.36456/farmasis.v4i2.7889

Yuliawati, A. N., & Ratnasari, P. M. D. (2020). Review Article: TinjauanAnjani, B. (2019). Analisis Efektivitas Biaya (Cost- Effectiveness) Antihipertensi Pada Pasien Hipertensi Komplikasi Diabetes Melitus Tipe 2 Rawat Inap Di Rsud Dr. Moewardi Tahun 2017. Publikasi Ilmiah. AMELIA, D. (2021). No 主観的健康感. Acta Holistica Pharmaciana, 2, 9–15.




DOI: http://dx.doi.org/10.52031/phrase.v4i2.902

Refbacks

  • There are currently no refbacks.